Free tool
FAERS Monitor: Jornay Pm
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209311 or its brand name (Jornay Pm, Methylphenidate Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
7,834
Serious
4,476
57% of reports
Hospitalization
1,746
Death reported
444
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,140
- headache420
- off label use385
- anxiety379
- fatigue373
- nausea353
- toxicity to various agents335
- insomnia321
- product substitution issue293
- somnolence289
- drug abuse285
- disturbance in attention259
- decreased appetite255
- suicidal ideation241
- agitation235
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 8 |
| 2009 | 18 |
| 2010 | 14 |
| 2011 | 18 |
| 2012 | 69 |
| 2013 | 117 |
| 2014 | 121 |
| 2015 | 440 |
| 2016 | 343 |
| 2017 | 495 |
| 2018 | 576 |
| 2019 | 464 |
| 2020 | 364 |
| 2021 | 413 |
| 2022 | 629 |
| 2023 | 832 |
| 2024 | 950 |
| 2025 | 1,019 |
| 2026 | 937 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,325 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product substitution issueSignal | 293 | 13.7 | 12.3 | 3,437 |
| disturbance in attentionSignal | 259 | 12.9 | 11.5 | 2,838 |
| drug abuseSignal | 285 | 9.2 | 8.2 | 2,082 |
| agitationSignal | 235 | 8.6 | 7.6 | 1,575 |
| suicidal ideationSignal | 241 | 7.1 | 6.3 | 1,255 |
| toxicity to various agentsSignal | 335 | 5.3 | 4.8 | 1,185 |
| somnolenceSignal | 289 | 3.9 | 3.4 | 614 |
| anxietySignal | 379 | 3.6 | 3.2 | 710 |
| insomniaSignal | 321 | 3.2 | 2.9 | 500 |
| decreased appetiteSignal | 255 | 2.9 | 2.6 | 330 |
| drug ineffectiveSignal | 1,140 | 2.3 | 2.2 | 915 |
| headache | 420 | 1.8 | 1.6 | 153 |
| fatigue | 373 | 1.3 | 1.2 | 24 |
| nausea | 353 | 1.2 | 1.1 | 12 |
| off label use | 385 | 1.2 | 1.1 | 11 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.